证券记录 · 已归档季度
AGIO
Agios Pharmaceuticals, Inc. · Healthcare · Biotechnology
19被追踪持有人
+2Δ持有人
22.49M持有股份
$902.53M报告持仓市值
+2新建仓位
−1清仓
动量输入（同类管理人）：
持有人广度 +11.8% ·
股份流向 -0.5% ·
净新建仓位 +5.3%
· 公式
持有人分散化：持有人数增多，合计持仓比例缩小。
所有持股数据：仅限已追踪的 13F 管理人，普通股持仓，报告期 Q3 2025
持股变化趋势
| 季度 | 持有人 | Δ | 股份 | 报告持仓市值 | 新增 | 清仓 |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 1.91M | $63.34M | n/a | −1 |
| Q2 2026 | 89 | +3 | 38.62M | $1.43B | +11 | −8 |
| Q1 2026 | 89 | 0 | 33.63M | $1.14B | +5 | −5 |
| Q4 2025 | 89 | -2 | 38.17M | $1.04B | n/a | −2 |
| Q3 2025 | 19 | +2 | 22.49M | $902.53M | +2 | −1 |
| Q2 2025 | 15 | 0 | 21.02M | $699.20M | n/a | n/a |
| Q1 2025 | 12 | -1 | 9.99M | $292.81M | n/a | −1 |
| Q4 2024 | 13 | +2 | 10.10M | $332.03M | +2 | n/a |
| Q3 2024 | 10 | 0 | 7.27M | $323.20M | n/a | n/a |
| Q2 2024 | 10 | n/a | 7.12M | $306.93M | n/a | n/a |
持有人 · Q3 2025
| # | 管理人 | 股份 | Δ股份 | 价值 | 其权重 | 持有 | ||
|---|---|---|---|---|---|---|---|---|
| 1 | The Vanguard Group ✦ (被动) | 5.60M | -1.4% | $224.98M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 2 | BlackRock ✦ (被动) | 4.55M | -6.0% | $182.47M | 0.0% | ▼ Trim | 2 | SEC ↗ ×13 |
| 3 | Wellington Management ✦ | 2.47M | +485.5% | $99.20M | 0.0% | ▲ Add | 6 | SEC ↗ ×7 |
| 4 | State Street Global Advisors ✦ (被动) | 2.26M | +16.0% | $90.83M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 5 | T. Rowe Price ✦ | 1.66M | -27.1% | $66.51M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 6 | Geode Capital Management ✦ (被动) | 1.42M | +0.8% | $56.86M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 7 | Fisher Asset Management ✦ | 870.14K | -0.8% | $34.93M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 8 | Goldman Sachs Group ✦ | 804.77K | n/a | $32.30M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 9 | Adage Capital Partners ✦ | 800.00K | +1.1% | $32.11M | 0.1% | ▲ Add | 4 | SEC ↗ |
| 10 | Citadel Advisors ✦ | 491.98K | -54.5% | $19.75M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 11 | Morgan Stanley ✦ | 417.00K | n/a | $16.74M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 12 | D. E. Shaw & Co. ✦ | 367.75K | -38.3% | $14.76M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 13 | JPMorgan Chase ✦ | 366.20K | n/a | $14.70M | 0.0% | n/c | 1 | SEC ↗ ×8 |
| 14 | Marshall Wace ✦ | 226.82K | -66.9% | $9.10M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 15 | AQR Capital Management ✦ | 91.64K | -5.4% | $3.61M | 0.0% | ▼ Trim | 6 | SEC ↗ ×5 |
| 16 | Two Sigma Investments ✦ | 59.63K | 新增 | $2.39M | 0.0% | New | 1 | SEC ↗ |
| 17 | Fidelity (FMR) ✦ | 20.71K | +11.4% | $831,364 | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 18 | Point72 Asset Management ✦ | 6.51K | 新增 | $261,190 | 0.0% | New | 1 | SEC ↗ |
| 19 | Millennium Management ✦ | 5.05K | -98.3% | $202,667 | 0.0% | ▼ Trim | 6 | SEC ↗ |
"持仓权重"指该仓位占该管理人13F申报股票组合市值的比例，即持仓信心指标。✦ = 精选管理人。
新增买入方
| Two Sigma Investments | $2.39M | 0.0% |
| Point72 Asset Management | $261,190 | 0.0% |
已清仓
| Norges Bank | $224,705 | 曾为 0.0% |
全市场背景: 涵盖所有13F申报机构（SEC结构化数据， Q1 2026): 231 持有人, 62.89M 股份, $1.99B 已申报. 这是与上方被追踪全域数据不同的较早期间，两者从不混用。
常见共同持仓
持有该证券的受追踪机构最常同时持有的其他证券：基于共同持有计数，而非基本面关联。
数据来源: 持股数据来源于已解析的13F普通股持仓（被追踪范围，变动对比集）；内部人行为来自Form 3/4/5；重大持股来自Schedule 13D/13G；所有文件均链接至SEC EDGAR原始申报。
报告期: Q3 2025 ·
方法论 ·
通过API获取此数据